Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Executive Summary
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
You may also be interested in...
Biosimilars: US FDA’s Updated Scientific Thinking Led To Interchangeability For Amgen's Wezlana
Pink Sheet’s Drug Review Profile explores Amgen’s Wezlana, an interchangeable biosimilar to Janssen’s Stelara. FDA determined late in the review that switching studies generally would not be needed for interchangeable ustekinumab products, prompting Amgen to seek the designation.
Remicade: A Study In Translational Looping
The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year